Folate therapy is recommended by both the American Psychiatric Association and the APA Task Force on Complementary and Alternative Medicine as a safe, effective option in depression with a favorable side effect profile. EnLyte is an advanced folate therapy used in the treatment of depression and hyperhomocysteinemia, with a pregnancy category A rating, that is gaining much attention and support in the Psychiatric community. Because it contains highly refined and metabolized folates and cofactors, it bypasses the MTHFR mutation, and others common in mood disorders. To assess it's effectiveness in sleep, Dr. Arnold Mech, MD of Mech HealthCare Associates, performed an open label study of EnLyte on sleep quality. According to Dr. Mech, 70% of patients with mood symptoms have a form of MTHFR, leaving them less able to efficiently convert folate (vitamin B9) and other B vitamins to their methylated, reduced form necessary for use in the production of neurotransmitters.
EnLyte was added to the treatment regimen for 4 weeks of 60 patients who had tested positive for one or two C677T allele MTHFR polymorphisms. Pre and post-EnLyte levels of fatigue were obtained per standard clinic protocol using the Fatigue Assessment Scale (FAS) and levels of emotional dysregulation (difficulties in frustration tolerance and impulse control) with the Mech Emotional Dysregulation Inventory (MEDI). At the end of the 4 weeks, most patients reported their sleep was significantly impr
Copyright©2014 Vocus, Inc.
All rights reserved